Topic

Vitrakvi (larotrectinib)

A collection of 35 issues

How to Get Vitrakvi (larotrectinib) Covered by Cigna in Florida: Complete PA Guide and Appeal Process

Answer Box: Getting Vitrakvi Covered by Cigna in Florida Cigna requires prior authorization for Vitrakvi (larotrectinib) with NTRK fusion confirmation via molecular testing, oncologist prescription, and documentation of metastatic/unresectable disease. Submit through CoverMyMeds or fax to 866-873-8279 using Florida Medical PA Form. Standard approval takes 72 hours; appeals must

How to Get Vitrakvi (Larotrectinib) Covered by Blue Cross Blue Shield in Ohio: Timeline, Appeals, and NTRK Testing Requirements

Quick Answer: Getting Vitrakvi Covered in Ohio Blue Cross Blue Shield in Ohio typically requires prior authorization for Vitrakvi (larotrectinib), with 15 business days for standard review or 72 hours for expedited cases. Success depends on complete NTRK fusion testing documentation, proof of metastatic/unresectable disease, and evidence of failed

How to Get Vitrakvi (Larotrectinib) Covered by Cigna in Michigan: Complete PA Guide and Appeal Scripts

Answer Box: Getting Vitrakvi Covered by Cigna in Michigan Vitrakvi (larotrectinib) requires prior authorization from Cigna for NTRK fusion-positive solid tumors that are metastatic or unresectable. Submit PA via CoverMyMeds or Evicore with molecular pathology report confirming NTRK fusion, oncologist prescription, and tumor staging documentation. If denied, Michigan residents have

Renewing Vitrakvi (Larotrectinib) Approval with Humana in Texas: Timeline, Documentation, and Bridge Options

Answer Box: Renewing Vitrakvi with Humana in Texas Humana Medicare requires prior authorization renewal for Vitrakvi (larotrectinib) every 6-12 months. Submit renewal 2-4 weeks before expiration with updated imaging showing response/stable disease, oncology notes, and liver function tests. If approval lapses, request a 31-day emergency supply under Humana'

How to Get Vitrakvi (Larotrectinib) Covered by UnitedHealthcare in North Carolina: Complete Prior Authorization and Appeals Guide

Answer Box: Quick Path to Vitrakvi Coverage To get Vitrakvi (larotrectinib) covered by UnitedHealthcare in North Carolina: Submit prior authorization via OptumRx with validated NTRK gene fusion test results, oncologist medical necessity letter documenting metastatic/unresectable disease, and prior therapy history. If denied, file internal appeal within 180 days, then

How to Get Vitrakvi (Larotrectinib) Covered by Aetna CVS Health in Washington: PA Forms, Appeals, and Cost-Saving Strategies

Answer Box: Getting Vitrakvi Covered by Aetna CVS Health in Washington Aetna CVS Health requires prior authorization for Vitrakvi (larotrectinib) with NTRK gene fusion testing documentation. Submit PA via CVS Specialty at 1-888-267-3277 with molecular pathology report showing NTRK1/2/3 fusion, oncologist prescription, and staging records. If denied, Washington

How to Get Vitrakvi (larotrectinib) Covered by UnitedHealthcare in Virginia: Prior Authorization Guide and Appeal Scripts

Answer Box: Getting Vitrakvi Covered by UnitedHealthcare in Virginia UnitedHealthcare requires prior authorization for Vitrakvi (larotrectinib) with specific criteria: confirmed NTRK gene fusion via validated testing, metastatic or unresectable solid tumor, and no known resistance mutations. Submit through OptumRx portal with molecular pathology report, staging documentation, and oncologist notes. Decisions

If Vitrakvi (Larotrectinib) Isn't Approved by Blue Cross Blue Shield of Michigan: Formulary Alternatives & Exception Paths

Answer Box: Quick Path Forward If Blue Cross Blue Shield of Michigan denies Vitrakvi (larotrectinib), you have three main options: try the covered NTRK inhibitor alternative (entrectinib/Rozlytrek if on formulary), request a formulary exception with documented medical necessity, or appeal the denial. Start by checking your specific plan'

Aetna CVS Health's Coverage Criteria for Vitrakvi (Larotrectinib) in Virginia: What Counts as "Medically Necessary"?

Answer Box: Getting Vitrakvi (Larotrectinib) Covered by Aetna CVS Health in Virginia Aetna CVS Health requires prior authorization for Vitrakvi with three key requirements: confirmed NTRK gene fusion via validated testing, metastatic/unresectable solid tumor status, and documented failure or unsuitability of standard therapies. The fastest path to approval: (1)

How to Get Vitrakvi (larotrectinib) Covered by Blue Cross Blue Shield in Pennsylvania: PA Forms, Appeals, and Success Strategies

Answer Box: Getting Vitrakvi Covered by Blue Cross Blue Shield in Pennsylvania Vitrakvi (larotrectinib) requires prior authorization from Blue Cross Blue Shield plans in Pennsylvania for NTRK fusion-positive solid tumors. The fastest path to approval: (1) Submit PA with confirmed NTRK fusion testing results and documentation of metastatic/unresectable disease,